Research programme: antibody therapeutics - Regeneron/Sanofi

Drug Profile

Research programme: antibody therapeutics - Regeneron/Sanofi

Alternative Names: ANG2 antibodies - Regeneron/Sanofi; Angiopoietin-2 antibodies - Regeneron/Sanofi; Anti-ANG2 antibodies - Regeneron/Sanofi; Anti-PDGF antibodies - Regeneron/Sanofi; Antibody collaboration - Regeneron/Sanofi; Therapeutic antibodies - Regeneron Pharmaceuticals/sanofi-aventis

Latest Information Update: 06 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Class Antibodies; Antineoplastics; Bispecific antibodies; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiopoietin-2 inhibitors; CD223 antigen inhibitors; CD274 antigen inhibitors; Immunomodulators; Platelet-derived growth factor receptor antagonists; TNFRSF18 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Eye disorders
  • Research Unspecified

Most Recent Events

  • 28 Jul 2015 Regeneron and Sanofi agree to co-promote and co-develop for the treatment of Cancer
  • 28 Jul 2015 Regeneron plans to initiate clinical trials in 2016 for Cancer
  • 03 May 2013 Regeneron Pharmaceuticals acquires full rights to antibodies targeting PDGF (in ophthalmology and all other indications) and ANG2 (in ophthalmology only) from Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top